母义明教授｜中国特色，全球智慧——中国糖尿病管理现状及展望
14.E Selvin, K Wattanakit, MW Steffes, et al., HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care, 2006. 29(4): p. 877-82.
15.KJ Bell, CE Smart, GM Steil, et al., Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care, 2015. 38(6): p. 1008-15.
16.J Lu, J He, M Li, et al., Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults. Diabetes Care, 2019. 42(8): p. 1539-1548.
17.中华医学会糖尿病学分会，中华医学会内分泌学分会, 中国成人2型糖尿病患者糖化血红蛋白控制目标及达标策略专家共识. 中华糖尿病杂志, 2020.
18.P Raskin, E Allen, P Hollander, et al., Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005. 28(2): p. 260-5.
19.RR Holman, KI Thorne, AJ Farmer, et al., Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med, 2007. 357(17): p. 1716-30.
20.T Wu, B Betty, M Downie, et al., Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes. Diabetes Ther, 2015. 6(3): p. 273-87.
